Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 20, 2024, the submission of three international patent applications. These applications, filed under the Patent Cooperation Treaty (PCT), are in collaboration with SciSparc Ltd., a company focusing on central nervous system disorders. The patents pertain to novel combinations of classic psychedelic substances including LSD, psilocybin, DMT, and SciSparc's proprietary compound Palmitoylethanolamide (PEA). Initially filed as provisional applications with the USPTO, these submissions expand Clearmind's intellectual property portfolio, which now comprises 27 granted patents and 24 pending applications across 15 families. The company's CEO, Dr. Adi Zuloff-Shani, emphasized the strategic move to protect their compounds in multiple countries, reinforcing their position in the psychedelic market. Clearmind, which is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, aims to develop and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements, particularly targeting alcohol use disorder among other health issues.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 20, 2024, the submission of three international patent applications. These applications, filed under the Patent Cooperation Treaty (PCT), are in collaboration with SciSparc Ltd., a company focusing on central nervous system disorders. The patents pertain to novel combinations of classic psychedelic substances including LSD, psilocybin, DMT, and SciSparc's proprietary compound Palmitoylethanolamide (PEA). Initially filed as provisional applications with the USPTO, these submissions expand Clearmind's intellectual property portfolio, which now comprises 27 granted patents and 24 pending applications across 15 families. The company's CEO, Dr. Adi Zuloff-Shani, emphasized the strategic move to protect their compounds in multiple countries, reinforcing their position in the psychedelic market. Clearmind, which is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, aims to develop and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements, particularly targeting alcohol use disorder among other health issues.
专门从事迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 于2024年2月20日宣布提交三项国际专利申请。这些申请是根据《专利合作条约》（PCT）提交的，是与专注于中枢神经系统疾病的公司ScisPARC Ltd. 合作的。这些专利涉及经典迷幻物质的新组合，包括迷幻药、迷幻药、DMT和ScisPARC的专有化合物棕榈酰乙醇胺（PEA）。这些提交最初是作为临时申请向美国专利商标局提交的，扩大了Clearmind的知识产权组合，现在包括15个家族的27项已获授权的专利和24项待处理的申请。该公司首席执行官阿迪·祖洛夫-沙尼博士强调了保护其化合物在多个国家的战略举措，以巩固他们在迷幻市场中的地位。Clearmind在纳斯达克、加拿大证券交易所和法兰克福证券交易所上市，旨在开发和商业化迷幻药类化合物，作为受管制药物、食品或补品，特别是针对酒精使用障碍和其他健康问题。
专门从事迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 于2024年2月20日宣布提交三项国际专利申请。这些申请是根据《专利合作条约》（PCT）提交的，是与专注于中枢神经系统疾病的公司ScisPARC Ltd. 合作的。这些专利涉及经典迷幻物质的新组合，包括迷幻药、迷幻药、DMT和ScisPARC的专有化合物棕榈酰乙醇胺（PEA）。这些提交最初是作为临时申请向美国专利商标局提交的，扩大了Clearmind的知识产权组合，现在包括15个家族的27项已获授权的专利和24项待处理的申请。该公司首席执行官阿迪·祖洛夫-沙尼博士强调了保护其化合物在多个国家的战略举措，以巩固他们在迷幻市场中的地位。Clearmind在纳斯达克、加拿大证券交易所和法兰克福证券交易所上市，旨在开发和商业化迷幻药类化合物，作为受管制药物、食品或补品，特别是针对酒精使用障碍和其他健康问题。
有用
没用